Monoclonal Antibody to Dynein, Axonemal, Heavy Chain 11 (DNAH11)
| Code | Size | Price |
|---|
| MAJ201Hu25-20ul | 20uL | £91.00 |
Quantity:
| MAJ201Hu25-100ul | 100ul | £172.00 |
Quantity:
| MAJ201Hu25-200ul | 200ul | £233.00 |
Quantity:
| MAJ201Hu25-1ml | 1ml | £537.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG2b Kappa
Antibody Clonality: Monoclonal
Antibody Clone: C9
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
DNAHBL; DNAHC11; DNHBL; DPL11; Dynein,Heavy Chain Beta-Like; Axonemal beta dynein heavy chain 11; Ciliary dynein heavy chain 11
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Dynein, Axonemal, Heavy Chain 11
Potency (Clone Number):
C9
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Dynein, Axonemal, Heavy Chain 11 (DNAH11) | RPJ201Hu02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||